icaritin and Scleroderma--Systemic
icaritin has been researched along with Scleroderma--Systemic* in 1 studies
Other Studies
1 other study(ies) available for icaritin and Scleroderma--Systemic
Article | Year |
---|---|
Icaritin Inhibits Skin Fibrosis through Regulating AMPK and Wnt/β-catenin Signaling.
Skin fibrosis is one of the major features of scleroderma. WNT/β-catenin signaling is associated with the progression of skin fibrosis. In this study, we aimed to determine the effect of icaritin (IT), a natural compound, on scleroderma-related skin fibrosis and its mechanisms. We found that IT could reduce the expression of COL1A1, COL1A2, COL3A1, CTGF, and α-SMA in human foreskin fibroblasts (HFF-1 cells), scleroderma skin fibroblasts (SSF cells), and TGF-β-induced HFF-1 cells. Wnt/β-catenin signaling was shown to be suppressed by IT. Additionally, IT activated AMPK signaling in HFF-1 cells. In conclusion, IT has an anti-skin fibrotic effect through activation of AMPK signaling and inhibition of WNT/β-catenin signaling. Our findings indicate the potential role of IT in the treatment of scleroderma and provide novel insight for the selection of drug therapy for scleroderma. Topics: Actins; AMP-Activated Protein Kinases; beta Catenin; Cell Line; Cell Survival; Collagen Type I; Collagen Type I, alpha 1 Chain; Fibroblasts; Flavonoids; Humans; Scleroderma, Systemic; Signal Transduction; Transforming Growth Factor beta; Wnt Proteins | 2021 |